drugset

drugset / Trial / NCT02246478

A Study of TAS-205 for Duchenne Muscular Dystrophy

NCT02246478 ↗

Phase 1 Completed 23 enrolled Taiho Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy.

Timeline

Start: 2014-09
Primary completion: 2015-06
Completion: 2015-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	TAS-205	Unknown	—	Oral

Indications